Get the Stockscreener App
65.55
2.25%
-1.51
After Hours:
66.19
0.64
+0.98%
Oruka Therapeutics Inc stock is traded at $65.55, with a volume of 1.40M.
It is down -2.25% in the last 24 hours and up +63.87% over the past month.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
See More
Previous Close:
$67.06
Open:
$67.45
24h Volume:
1.40M
Relative Volume:
2.11
Market Cap:
$3.25B
Revenue:
-
Net Income/Loss:
$-105.43M
P/E Ratio:
-28.28
EPS:
-2.3183
Net Cash Flow:
$-88.42M
1W Performance:
+5.71%
1M Performance:
+63.87%
6M Performance:
+134.86%
1Y Performance:
+665.77%
1-Day Range:
$64.88
$67.94
1-Week Range:
$59.00
$67.94
52-Week Range:
$8.31
$67.94
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
65.55 | 3.32B | 0 | -105.43M | -88.42M | -2.3183 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Piper Sandler | Overweight |
| Nov-13-25 | Initiated | Jefferies | Buy |
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Oruka Therapeutics stock hits 52-week high at 64.72 USD By Investing.com - Investing.com Australia
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - The Manila Times
The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments | DelveInsight - GlobeNewswire Inc.
Does Oruka Therapeutics' (ORKA) US$1 Billion Shelf Clarify or Complicate Its Capital Strategy? - simplywall.st
ORKA Maintained by BTIG -- Price Target Raised to $78 - GuruFocus
H.C. Wainwright raises Oruka Therapeutics price target to $70 - Investing.com
H.C. Wainwright raises Oruka Therapeutics price target to $70 By Investing.com - Investing.com Canada
BTIG raises Oruka Therapeutics price target on trial timeline By Investing.com - Investing.com Canada
Up nearly 840% in a year, does this 'strong buy' stock have more room to run? - MSN
[EFFECT] Oruka Therapeutics, Inc. SEC Filing - Stock Titan
This Startup’s Psoriasis Drug Studies Have Lifted Its Stock - Barron's
Stifel reiterates Oruka Therapeutics stock rating ahead of trial data By Investing.com - Investing.com Canada
ORKA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Up Nearly 840% in a Year, Does This ‘Strong Buy’ Stock Have More Room to Run? - Yahoo Finance
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 5% After Analyst Upgrade - Defense World
How cyclical is Oruka Therapeutics Incs revenue streamPrice Action & Community Verified Watchlist Alerts - baoquankhu1.vn
Oruka Therapeutics Is Maintained at Overweight by Barclays - Moomoo
UBS Sticks to Its Buy Rating for Oruka Therapeutics (ORKA) - The Globe and Mail
Barclays Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $78 - Moomoo
Oruka Therapeutics (NASDAQ:ORKA) Given New $75.00 Price Target at UBS Group - Defense World
Does Oruka Therapeutics' (ORKA) $1 Billion Shelf Plan Reframe Its Long-Term Capital Strategy? - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Price Target Raised to $75.00 at UBS Group - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Hits New 52-Week HighHere's Why - MarketBeat
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Raises Target Price to $75 - Moomoo
Guggenheim raises Oruka Therapeutics price target on trial outlook By Investing.com - Investing.com Canada
Secure Asset Management LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
ORKA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oruka Therapeutics may offer up to $1 billion of securities from time to timeSEC filing - marketscreener.com
Oruka Therapeutics May Offer Up To $1 Billion Of Securities From Time To TimeSEC Filing - TradingView
Oruka Therapeutics (NASDAQ: ORKA) files $1B shelf to sell equity, warrants - Stock Titan
Oruka Therapeutics stock hits 52-week high at 50.11 USD By Investing.com - Investing.com Australia
HC Wainwright & Co. Maintains Oruka Therapeutics (ORKA) Buy Recommendation - MSN
ORKA-001 Phase 1 Completion: What Oruka’s First-in-Human Milestone Means for Investors - TipRanks
Oruka Therapeutics stock hits 52-week high at 50.11 USD - Investing.com
Oruka Therapeutics (NASDAQ:ORKA) Sets New 12-Month HighShould You Buy? - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Short Interest Down 18.4% in March - MarketBeat
How does Oruka Therapeutics Inc compare to its peersProfit Target & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Oruka Therapeutics and Clearmind Medicine Vie for Investor Dollars - National Today
Vanguard realignment leaves Oruka Therapeutics (ORKA) holdings at 0 after disaggregation - Stock Titan
458,946 Shares in Oruka Therapeutics, Inc. $ORKA Acquired by Synergy Asset Management LLC - marketbeat.com
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 5.6%Here's Why - MarketBeat
Oruka Therapeutics stock hits 52-week high at 43.0 USD By Investing.com - Investing.com Australia
Momentum Shift: Will Oruka Therapeutics Inc benefit from AI trendsQuarterly Profit Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Oruka Therapeutics (NASDAQ:ORKA) Hits New 12-Month HighShould You Buy? - MarketBeat
Oruka Therapeutics stock hits 52-week high at 43.0 USD - Investing.com
Aug Selloffs: Will Oruka Therapeutics Inc outperform tech stocksQuarterly Investment Review & AI Powered Market Entry Strategies - baoquankhu1.vn
Does Oruka’s Widening Loss and ESOP Shelf Registration Change The Bull Case For Oruka Therapeutics (ORKA)? - Yahoo Finance
Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight By Investing.com - Investing.com Canada
Piper Sandler reiterates Oruka Therapeutics stock rating at Overweight - Investing.com
Oruka Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | | US6876041087 - marketscreener.com
Oruka Therapeutics Inc Stock (ORKA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):